GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing

Información del proyecto

GATBIO NEXT

Identificador del acuerdo de subvención: 101114204

DOI

10.3030/101114204

Proyecto cerrado

Fecha de la firma de la CE 31 Mayo 2023

Fecha de inicio 1 Junio 2023

Fecha de finalización 31 Mayo 2024

Financiado con arreglo a

• European innovation ecosystems

Coste total

Sin datos

Aportación de la UE

€ 75 000,00

Coordinado por

GAT BIOSCIENCES SL
Spain

Periodic Reporting for period 1 - GATBIO NEXT (GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing)

Período documentado: 2023-06-01 hasta 2024-05-31

Resumen del contexto y de los objetivos generales del proyecto

GAT Biosciences S.L. (GATBIO) is a preclinical stage Biotech SME developing next generation of accessible and non-injected (oral) biopharmaceuticals through proprietary and sustainable microalgal biofactories. Our first candidate is GB-AF-004, an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases (IBDs). GB-AF-004 has the potential to highly impact the quality of life of millions of IBD’s patients worldwide as an affordable, low toxicity and long-term efficacy therapy for Ulcerative Colitis and Crohn's patients.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

GATBIO’s WomenTechEu Project has explored the best therapeutic positioning for GB-AF-004, based on a deep analysis of current therapeutic options for IBD and their limitations, working in collaboration with leaders of opinion in the clinical management of IBD.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Biologic anti-inflammatory therapies have already proven to be highly effective treatments for the induction and remission control of IBD's flares. Still, all available anti-inflammatory biologics are administered by injection and their systemic administration is related to site-effects and middle-terms loss of efficacy. GB-AF-004, a new class of anti-inflammatory antibody of enhanced properties to harsh intestinal atmosphere, has the potential to become the first oral anti-inflammatory biologic for IBDs management, acting specifically and locally in the damaged intestinal tissue without systemic immunosuppression and for long-term non-invasive, accessible and affordable treatments. IBDs includes a range of chronic and painful autoimmune diseases affecting locally the intestine, affecting patients from their youth and throughout life and of unknown causes. More than 10 million people are affected by IBD.